Fourth quarter and full year 2022 results

Fourth quarter and full-year 2022 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.

(14h00 - 15h30 CET / 8:00 - 9:30am EST)

Featuring

Paul Hudson

Chief Executive Officer

Jean-Baptiste de Chatillon

Chief Financial Officer

Bill Sibold

Specialty Care

Olivier Charmeil

General Medicines

John Reed

R&D

Thomas Triomphe

Vaccines

Julie Van Ongevalle

Consumer Healthcare

Roy Papatheodorou

General Counsel

Highlights

With ten consecutive quarters of growth, the progress we’ve made in the past three years speaks for itself. As we launch the next phase of our strategy, our continued commitment to investing in the science will be crucial to maintaining a steady-state cadence of first and best in class medicines.